RYTM
NASDAQRhythm Pharmaceuticals Inc.
Price$106.69+1.63 (+1.55%)
01:30 PM07:45 PM
News · 26 weeks87+25%
2026-01-182026-07-12
Mix3190d
- SEC Filings9(29%)
- Other9(29%)
- Insider9(29%)
- Earnings3(10%)
- Leadership1(3%)
Latest news
25 items- PRRhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic ObesityBOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM). The TRANSCEND study is the largest and longest placebo-controlled clinical trial ever conducted in patients with acquired hypothalamic obesity. The publication highlights robust improvements in weight and hunger achieve
- INSIDERChief Scientific Officer Garfield Alastair converted options into 4,445 shares and covered exercise/tax liability with 2,150 shares, increasing direct ownership by 30% to 10,058 units (SEC Form 4) to cover taxes4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Jean Christophe converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Mcgirr David W J converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Tetrault Lynn A. converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Arbuckle Stuart A converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERDirector Good Jennifer L converted options into 4,712 shares, increasing direct ownership by 67% to 11,712 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- SECRhythm Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- INSIDERDirector Tetrault Lynn A. exercised 37,000 shares at a strike of $28.27 and sold $3,711,896 worth of shares (37,000 units at $100.32) as part of a pre-agreed trading plan (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- SECSEC Form 144 filed by Rhythm Pharmaceuticals Inc.144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
- SECRhythm Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- PRRhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO at 2.5 years -- -- Bivamelagon therapy achieved progressive reductions in BMI and hunger measures in patients (N=26) with acquired HO at one year -- -- Real-world data showed patients with BBS treated with setmelanotide (N=286) achieved improvements in weight-related outcomes, reduction in healthcare resource utilization -- -- Additional presentations highlight analyses of setmelanotide therapy in patients with acquired HO who achieved weight category improvements; BMI reductions after prior bariatric surgery in acquired HO patients treated with setmelanotide; and po
- PRRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS -- -- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET -- BOSTON, June 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary data from a Phase 2 trial
- PRRhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeBOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company's Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). David Meeker, M.D., Chairman, President and Chief Executive Officer will be joined by Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine to discuss the data. Conference Ca
- SECSEC Form DEFA14A filed by Rhythm Pharmaceuticals Inc.DEFA14A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- PRRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago. Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, will present results from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), evaluating higher doses and longer treatment duratio
- PRRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). "Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria," was published in the peer-reviewed American Journal of Medical Genetics. This simplified and practical diagnostic algorithm for healthcare practitioners is designed to reduce time to an informed diagnosis of BBS. A multidisciplinary group of int
- PRRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesBOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at two upcoming conferences. Hunter Smith will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026 at 12:50 p.m. ET; andDavid Meeker will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday,
- INSIDERChief Financial Officer Smith Hunter C exercised 3,000 shares at a strike of $17.87, increasing direct ownership by 3% to 119,611 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERCorporate Controller & CAO German Christopher Paul exercised 4,442 shares at a strike of $42.17 and sold $428,131 worth of shares (4,643 units at $92.21), closing all direct ownership in the company (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
- PRRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO – – New research highlights the burden and under recognition of hyperphagia – BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Rhythm and its collaborators will present six posters, including four featu
- PRRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceBOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m. PT in Las Vegas. The fireside chat will be webcasted and available under "Events & Presentations" in the Investor Relations section of the Company's website at www.rhythmtx.com. A replay of the webcast will be available on the Rhythm website for 30 da
- SECSEC Form S-8 filed by Rhythm Pharmaceuticals Inc.S-8 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- SECSEC Form DEFA14A filed by Rhythm Pharmaceuticals Inc.DEFA14A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
RYTM FAQ
7 questionsWhat does Rhythm Pharmaceuticals Inc. do?
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities...Where does RYTM stock trade?
Rhythm Pharmaceuticals Inc. (RYTM) is listed on NASDAQ.What sector and industry is RYTM in?
Rhythm Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rhythm Pharmaceuticals Inc. go public?
Rhythm Pharmaceuticals Inc. (RYTM) completed its IPO in 2017.What are analysts saying about RYTM?
Rhythm Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Outperform on 2026-02-19.What companies are similar to RYTM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RYTM side-by-side with any of them on Quantisnow.How can I track RYTM on Quantisnow?
Quantisnow aggregates Rhythm Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RYTM to receive live email and push alerts on every new disclosure.